Dapansutrile is a selective and orally active NLRP3 inflammasome inhibitor which reverses the metabolic cost of inflammation. In vitro, nanomolar concentrations of Dapansutrile reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3.

OLT1177® is a registered trademark of Olatec Therapeutics LLC in the United States and other countries.

KEYWORDS: Dapansutrile | Supplier | NLRP3 inhibitor | CAS [54863-37-5] | NF-κB pathway | NLR | Inhibitor | Receptors | Autoimmune encephalomyelitis | Cryopyrin